Latest Roche Group Stories
TUCSON, Ariz., Sept. 1, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc., (Ventana) a member of the Roche Group, will unveil its newest digital pathology solution designed to increase efficiency and throughput in today's anatomic pathology laboratories. The new product will be unveiled at the College of American Pathologists (CAP) 2011 annual meeting on Sept. 11, 2011, at 12:12 pm in Ventana booth # 105. The real promise associated with the transition to digital pathology is an evolution...
TUCSON, Ariz., Aug. 2, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today the launch of BenchMark ULTRA with new Ultimate Reagent Access (URA). BenchMark ULTRA with URA is the world's first platform that allows laboratories to process individual immunohistochemistry (IHC) and in situ hybridization (ISH) samples as soon as they arrive in the lab. This enhancement allows labs to quickly respond to unpredictable changes in workflow,...
TUCSON, Ariz., Aug. 1, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today the appointment of Mara Aspinall to the role of President, Ventana Medical Systems, Inc. Aspinall was most recently Founder, President, and CEO of On-Q-ity, a start-up diagnostics company focused on circulating tumor cell technology. (Photo: http://photos.prnewswire.com/prnh/20110801/LA44346) Prior to this, Aspinall spent twelve years with Genzyme Corporation...
TUCSON, Ariz., July 26, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today the launch of their OptiView DAB IHC Detection Kit, the first fully-automated immunohistochemistry (IHC) detection kit that combines both sensitive chemistry and flexible software to deliver highly customizable staining. OptiView Detection significantly enhances stain quality, allowing pathologists to view IHC assays more clearly than ever before. (Photo:...
TUCSON, Ariz., July 19, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm is a global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm...
TUCSON, Ariz., June 14, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that the FDA approved the INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) for commercialization in the United States. This is the first fully automated assay approved by the FDA for determination of HER2 gene status in breast cancer as an aid in the assessment of patients considered for treatment with Herceptin (trastuzumab). For breast cancer...
PARSIPPANY, N.J. and TOKYO, May 11, 2011 /PRNewswire/ -- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, a pre-marketing application for approval for a companion diagnostic test has been submitted in the U.S.; the test also will be registered in Europe. Vemurafenib is an oral,...
TUCSON, Ariz., March 31, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc., a member of the Roche Group, announced today the availability of its next generation Virtuoso digital pathology application software. (Photo: http://photos.prnewswire.com/prnh/20110331/LA74593) The new version of Virtuoso software expands pathologists' workflow capabilities with features that deliver additional gains in efficiency, collaboration, and productivity. Pathology labs worldwide will realize...
TOORAK, Australia, Jan. 14, 2011 /PRNewswire/ -- Circadian Technologies (ASX.CIR) is very pleased to announce today that its subsidiary company Vegenics Pty Limited, has been granted an exclusive, global licence by Chugai Pharmaceutical Co, Ltd. granting access to Chugai IP relating to VEGF-D. Circadian and Chugai both hold extensive VEGF-D IP portfolios which have overlapped throughout the world. This licence enables Circadian to enhance its intellectual property portfolio and secure its...
PLEASANTON, Calif., July 13 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester. Financial details were not...
